In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 - PubMed (original) (raw)
doi: 10.1158/1535-7163.MCT-06-0543. Epub 2007 Jan 31.
Randy T McConnell, Derek R Duckett, Glenn M Spehar, Victoria B Knick, Daniel F Hassler, Nobuhiro Noro, Masaaki Furuta, Kyle A Emmitte, Tona M Gilmer, Robert A Mook Jr, Mui Cheung
Affiliations
- PMID: 17267659
- DOI: 10.1158/1535-7163.MCT-06-0543
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Timothy J Lansing et al. Mol Cancer Ther. 2007 Feb.
Abstract
Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-molecule inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, we have examined the in vitro biological activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potently inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G(2)-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G(2)-M and show little apoptosis. We also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool molecule for further investigation of the biological functions of PLK1 and PLK3.
Similar articles
- The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X. Li L, et al. Acta Pharmacol Sin. 2009 Oct;30(10):1443-53. doi: 10.1038/aps.2009.141. Acta Pharmacol Sin. 2009. PMID: 19801998 Free PMC article. - Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS. Nihal M, et al. Cell Cycle. 2011 Apr 15;10(8):1303-11. doi: 10.4161/cc.10.8.15353. Epub 2011 Apr 15. Cell Cycle. 2011. PMID: 21436619 - Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA. Vazquez-Martin A, et al. Cell Cycle. 2011 Apr 15;10(8):1295-302. doi: 10.4161/cc.10.8.15342. Epub 2011 Apr 15. Cell Cycle. 2011. PMID: 21474997 - Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA, Raab M, Becker S, Strebhardt K. Raab CA, et al. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188467. doi: 10.1016/j.bbcan.2020.188467. Epub 2020 Nov 7. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33171265 Review. - Polo-like kinases inhibitors.
Garuti L, Roberti M, Bottegoni G. Garuti L, et al. Curr Med Chem. 2012;19(23):3937-48. doi: 10.2174/092986712802002455. Curr Med Chem. 2012. PMID: 22709006 Review.
Cited by
- Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A. Haupenthal J, et al. Neoplasia. 2012 May;14(5):410-9. doi: 10.1596/neo.111366. Neoplasia. 2012. PMID: 22745587 Free PMC article. - DNA Double-Strand Break Resection Occurs during Non-homologous End Joining in G1 but Is Distinct from Resection during Homologous Recombination.
Biehs R, Steinlage M, Barton O, Juhász S, Künzel J, Spies J, Shibata A, Jeggo PA, Löbrich M. Biehs R, et al. Mol Cell. 2017 Feb 16;65(4):671-684.e5. doi: 10.1016/j.molcel.2016.12.016. Epub 2017 Jan 26. Mol Cell. 2017. PMID: 28132842 Free PMC article. - Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis.
Hu CK, Ozlü N, Coughlin M, Steen JJ, Mitchison TJ. Hu CK, et al. Mol Biol Cell. 2012 Jul;23(14):2702-11. doi: 10.1091/mbc.E12-01-0058. Epub 2012 May 23. Mol Biol Cell. 2012. PMID: 22621898 Free PMC article. - A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, Donson A, Alimova I, Sullivan KD, Joshi M, Erlander M, Ridinger M, Foreman NK, Venkataraman S, Vibhakar R. Wang D, et al. Neuro Oncol. 2022 Mar 12;24(3):414-426. doi: 10.1093/neuonc/noab207. Neuro Oncol. 2022. PMID: 34477871 Free PMC article. - Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
Chen L, Ahmad N, Liu X. Chen L, et al. Cell Cycle. 2016;15(6):840-9. doi: 10.1080/15384101.2016.1151582. Cell Cycle. 2016. PMID: 26900800 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous